Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.

Beaumont A, Durand C, Ledrans M, Schwoebel V, Noel H, Le Strat Y, Diulius D, Colombain L, Médus M, Gueudet P, Mouly D, Aumaître H

Open source

DOI
10.1136/bmjopen-2021-053201
Published
2021 Nov 23
Container
BMJ open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2021-053201,
  title = {Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.},
  author = {Beaumont A and Durand C and Ledrans M and Schwoebel V and Noel H and Le Strat Y and Diulius D and Colombain L and Médus M and Gueudet P and Mouly D and Aumaître H},
  year = {2021},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2021-053201},
  url = {https://doi.org/10.1136/bmjopen-2021-053201}
}

RIS

TY  - JOUR
TI  - Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.
AU  - Beaumont A
AU  - Durand C
AU  - Ledrans M
AU  - Schwoebel V
AU  - Noel H
AU  - Le Strat Y
AU  - Diulius D
AU  - Colombain L
AU  - Médus M
AU  - Gueudet P
AU  - Mouly D
AU  - Aumaître H
PY  - 2021
JO  - BMJ open
DO  - 10.1136/bmjopen-2021-053201
UR  - https://doi.org/10.1136/bmjopen-2021-053201
ER  - 

APA

A, B., C, D., M, L., V, S., H, N., Y, L. S., D, D., L, C., M, M., P, G., D, M., & H, A. (2021). Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.. BMJ open. https://doi.org/10.1136/bmjopen-2021-053201

Source records